Semaglutide and tirzepatide are remarkable medications. The STEP trials showed roughly 15 percent body weight loss with semaglutide. SURMOUNT showed up to 22 percent with tirzepatide. These results are real and they are reshaping medicine. They are also being prescribed badly by most online clinics.
The pattern looks like this: you fill out a short form, an algorithm checks your BMI, a provider you'll never speak to writes a prescription, and the compound pharmacy ships your weekly pen. No labs. No metabolic context. No conversation about muscle preservation. No plan for what happens when you discontinue. This article is about what's missing and why it matters.
Why the metabolic workup matters more than the BMI screen
BMI is a crude proxy for metabolic dysfunction. Two patients with the same BMI of 32 can have radically different metabolic profiles. One has fasting insulin of 22 µIU/mL, HbA1c of 5.9, fatty liver, and the full picture of insulin resistance. The other has fasting insulin of 6 µIU/mL, HbA1c of 5.2, normal lipids, and is metabolically healthier than most people at BMI 25.
Both will lose weight on tirzepatide. But the first patient — the metabolically dysfunctional one — needs ongoing medication and lifestyle reconstruction to maintain results. The second patient may have a behavioral or hormonal issue (cortisol, sleep, thyroid) driving weight gain that GLP-1 will mask but not address.
Without measuring fasting insulin, HOMA-IR, full lipids including ApoB, liver enzymes, and HbA1c, you cannot actually tell which patient is in front of you. The standard prescription is the same. The right protocol is not.
The thyroid component nobody screens for
Thyroid dysfunction drives weight gain and blunts the response to weight-loss interventions. The standard PCP screen is TSH alone. The clinically useful screen is TSH, Free T4, Free T3, reverse T3, and antibodies. About one in eight women in their 40s presents with subclinical thyroid issues that depress metabolic rate, energy, and the response to weight-loss therapy.
Prescribing GLP-1 to a patient with low Free T3 and elevated reverse T3 still produces weight loss, because GLP-1 works upstream. But the patient feels worse than she should, loses muscle she shouldn't, and rebounds harder when she discontinues. Treating the thyroid first or in parallel changes the trajectory dramatically.
The muscle preservation problem
Roughly 25 to 40 percent of GLP-1 weight loss is lean mass, depending on the study and the protocol. For a 200-pound patient losing 30 pounds, that is potentially 7-12 pounds of muscle, bone, and connective tissue. This matters enormously for long-term metabolic health, fall risk, and the ability to maintain results.
The interventions that protect lean mass are well-established and absent from most online GLP-1 protocols:
- Adequate protein intake — at least 1.2 g/kg of goal body weight, often higher. Most patients on GLP-1 reduce intake reflexively because they're not hungry; they need a structured plan.
- Resistance training — 2-3 sessions per week minimum. The compound that triggers muscle protein synthesis is mechanical load, not the medication.
- Creatine monohydrate — 5g daily. Cheap, well-studied, modestly muscle-sparing during weight loss.
- Optionally, peptide co-therapy — CJC-1295/Ipamorelin or BPC-157 for patients with adequate baseline IGF-1 and physician oversight.
None of this is on a Henry Meds or Mochi prescription. It should be.
The discontinuation question
GLP-1 weight loss reverses partially or fully when patients stop the medication. The STEP-4 trial showed roughly two-thirds of weight returning within 12 months of discontinuation. This is not a failure of the drug — it's the nature of treating a chronic condition with a medication that the body adapts to over time.
The clinical question is not "do you want to lose weight?" It is "what does the next 5-10 years of metabolic care look like?" Patients deserve to understand:
- Whether they're likely to need long-term, intermittent, or short-course GLP-1 therapy
- What lifestyle and protocol architecture supports maintenance
- What the off-ramp looks like and what biomarkers to monitor
- How dose tapering works and when to reassess
Most online GLP-1 prescribers do not have this conversation because their model is transactional. KAYU does.
What KAYU does differently
Every patient on a GLP-1 protocol at KAYU starts with the full metabolic panel: fasting insulin, HOMA-IR, HbA1c, fasting glucose, full thyroid, ApoB, liver function, kidney markers, and a complete CBC. Your physician interprets this as a system before writing a prescription.
The protocol includes an explicit muscle preservation plan, a re-assessment at 60 and 120 days, and a defined approach to maintenance and eventual discontinuation. The medication is one component, not the entire intervention.
Start with a $49 one-time consult (credits to your first peptide/hormone order or first month of any membership). Root is $199/mo and includes quarterly peptide bloodwork plus 20% off peptides. Branch ($499/mo) adds hormones and 30% off; Canopy ($799/mo) is concierge with 40% off. KAYU bills you directly through Stripe; compounded GLP-1 typically runs $300-$450/month for tirzepatide before the membership discount.
Take the 2-minute KAYU assessment to see how your metabolic profile maps to a GLP-1 protocol that's actually built for you.
This article is educational. It does not substitute for a physician-patient relationship. GLP-1 medications carry contraindications and side effects your physician will review during your consult.